GPhA’s Biosimilars Council Will Ratchet Up Advocacy, Seek New Partners
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand companies welcome but unlikely to join because of policy differences; educational handbook compares biosimilars to biologic manufacturing changes.
You may also be interested in...
GPhA And Actavis Divorcing: Biosimilars Behind The Rift
Actavis, the hybridizing generics giant that once helped keep GPhA together, now appears to be splitting off in a dispute over state substitution strategy.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.